{"id":"W4377944155","doi":"10.1016/j.jtho.2023.05.015","title":"Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Astellas Pharma; Yuhan; BeiGene; G1 Therapeutics; Pfizer; Genentech; American Association for Cancer Research; AstraZeneca; Daiichi Sankyo Europe; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Discontinuation; Osimertinib; Tolerability; Placebo; Internal medicine; Adverse effect; Oncology; Surgery; Cancer; Adenocarcinoma; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00432666,0.000533961,0.001096058,0.0003397235,0.0002258122,0.0007782227,0.0004532434,0.0004053115,0.001149908],"category_scores_gemma":[0.001841515,0.0002333576,0.002530897,0.0005832109,0.0002837965,0.0004726606,0.00030551,0.001084729,0.0001933813],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004456783,"about_ca_system_score_gemma":0.0004402712,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008519065,"about_ca_topic_score_gemma":0.002459697,"domain_scores_codex":[0.9990137,0.0005520734,0.00007563261,0.0001016074,0.0001810459,0.0000760221],"domain_scores_gemma":[0.9974973,0.0006186157,0.001335395,0.0001615017,0.0001775345,0.0002096639],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4270242,0.003017054,0.4248787,0.002128492,0.02094986,0.0001896107,0.0003448655,0.002856138,0.009001521,0.0001494519,0.005836147,0.1036239],"study_design_scores_gemma":[0.05870146,0.04076524,0.876029,0.0002072509,0.01503945,0.0004623796,0.0001115192,0.001384836,0.001963929,0.0002102233,0.005049666,0.00007510743],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9872034,0.008548569,0.0002905705,0.0001790964,0.00003238173,0.0002180278,0.002491314,0.00001884513,0.00101768],"genre_scores_gemma":[0.9904554,0.002456864,0.0003817879,0.0002689408,0.0001230571,0.0002968062,0.005553352,0.000009540929,0.0004542047],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00432666,"threshold_uncertainty_score":0.02288181,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05695210664319922,"score_gpt":0.4782207666485358,"score_spread":0.4212686600053366,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}